OncoCEE-BR detects CTCs, which are rare, and determines the patient’s HER2 status by fluorescence in situ hybridization (FISH).
The companies will market and sell the OncoCEE-BR CTC test to hospitals, pathologists and medical oncologists.
Biocept will perform the test in its laboratory and results will be interpreted and reported by Clarient’s pathology group.
Clarient chief commercial officer Dave Daly said Biocept’s OncoCEE-BR is an important test for their oncology portfolio, and will help the oncology community progress towards more personalized cancer care.